JFDA extended the implementation deadline for DataMatrix and serialization on secondary packaging on regulated pharmaceutical products until 31 March 2024
Jordan Food and Drug Association (JFDA) published a new circular regarding barcoding and serialization on secondary packaging on regulated pharmaceutical products. In the document is stated that the deadline is postponed to 31 March 2024.
Serialization & Trace and Trace
Jordan`s journey toward the implementation of pharma serialization started in 2017. Since then a lot of changes have been made, including several extensions of this exact deadline. According to the new circular, by the end of March, all pharma supply chain participants in Jordan must be prepared with the requirements for DataMatrix and serialization – (Global Trade Item Number – GTIN; Serial Number (SN); Batch/ Lot number; Expiry date).
The pharmaceutical market impacts significantly the Jordanian economy. The projected revenue of the pharma market is expected to reach USD 333,90 million. The prognosis for 2024-2028 shows that the market volume could reach USD 442,40 million by 2028. Oncology Drugs are in a leading position on the market – the sector`s projected volume of USD 62,31 million this year.
Pharma industry in Jordan – Potential & Growth
The government proactively supports the Healthcare sector in Jordan because of its great potential. Several reforms, programs, and initiatives were launched to foster the growth of life science. In the “Investment Promotion Strategy 2023-2026”, Pharmaceuticals are listed among the “High-Value Industries” and sectors of priority. The analysis highlighted that one of the priority objectives is to develop the pharma industry`s potential for licensing and joint venture partnerships between local and multinational pharma companies to produce products for export to EU and regional markets. The implementation of serialization and track and trace has a crucial role in this process of development because the traceability will enhance the regulatory process, and level of drugs` safety and quality, as well as prove the implementation of global standards.
Sources:
https://www.moin.gov.jo/EBV4.0/Root_Storage/AR/Investment-Promotion-Startegy-MOIN.pdf
https://www.statista.com/outlook/hmo/pharmaceuticals/jordan#revenue
